In this video segment, Motley Fool health care bureau chief Brenton Flynn looks at Medivation (MDVN +0.00%). Shares already have a lot of high expectations priced in, and the company's prostate cancer drug Xtadi sells at a 30% premium compared to competitor Zytiga from Johnson & Johnson. With similar efficacy, what will Medivation need to do to help justify the premium pricing of both its drug and stock?